BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30512144)

  • 1. [Not Available].
    Strandberg K
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512144
    [No Abstract]   [Full Text] [Related]  

  • 2. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
    Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
    Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring options and reversal agents for oral anticoagulants].
    Thorup SB; Husted SE; Vang ML
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory monitoring of the non-vitamin K oral anticoagulants.
    Blann AD; Lip GY
    J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
    Adcock DM; Gosselin R
    Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Large studies of NOAC shows good and safe stroke protection].
    Hijazi Z; Oldgren J
    Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
    [No Abstract]   [Full Text] [Related]  

  • 13. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
    Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
    J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
    Lindahl S; Dyrkorn R; Spigset O; Hegstad S
    Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
    Ebner M; Peter A; Spencer C; Härtig F; Birschmann I; Kuhn J; Wolf M; Winter N; Russo F; Zuern CS; Blumenstock G; Ziemann U; Poli S
    Stroke; 2015 Oct; 46(10):2741-7. PubMed ID: 26272385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of direct oral anticoagulant assay use in clinical practice.
    Gu TM; Garcia DA; Sabath DE
    J Thromb Thrombolysis; 2019 Apr; 47(3):403-408. PubMed ID: 30600427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of apixaban concentrations in real‑world clinical and laboratory settings: the first Polish experience.
    Góralczyk T; Papuga-Szela E; Żuk J; Undas A
    Pol Arch Intern Med; 2018 May; 128(5):324-326. PubMed ID: 29768395
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
    Kuhn J; Gripp T; Flieder T; Hammerschmidt A; Hendig D; Faust I; Knabbe C; Birschmann I
    Clin Chim Acta; 2018 Nov; 486():347-356. PubMed ID: 30114406
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
    Jain N; Reilly RF
    Clin J Am Soc Nephrol; 2019 Feb; 14(2):278-287. PubMed ID: 29802125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.